No open-market selling at CervoMed Inc. in the past year, which is unusual. Instead five corporate insiders bought about $3.7 million worth of CRVO.
Biggest single buyer: BOGER JOSHUA S, Director, with roughly $3 million. C-suite participation is part of the picture here.
No open-market insider buying or selling in the last full quarter. Insiders bought in 3 of the last 7 full quarters. 37 investment managers listed CRVO in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | BOGER JOSHUA S | Director | Buy | 955,414 | $3.14 | $3.0M | SEC |
| Nov 19, 2025 | Winton Matthew | Executive Officer | Buy | 1,500 | $7.95 | $12K | SEC |
| Nov 19, 2025 | Winton Matthew | Executive Officer | Buy | 3,500 | $8.43 | $30K | SEC |
| Nov 19, 2025 | Gregoire Sylvie | Director | Buy | 10,793 | $8.46 | $91K | SEC |
| Nov 19, 2025 | Gregoire Sylvie | Director | Buy | 10,807 | $8.46 | $91K | SEC |
| Nov 19, 2025 | ELDER WILLIAM ROBERT | CFO | Buy | 1,000 | $8.45 | $8K | SEC |
| Nov 19, 2025 | ELDER WILLIAM ROBERT | CFO | Buy | 2,500 | $8.32 | $21K | SEC |
| Nov 19, 2025 | ALAM JOHN J | CEO | Buy | 10,807 | $8.46 | $91K | SEC |
| Nov 19, 2025 | ALAM JOHN J | CEO | Buy | 10,793 | $8.46 | $91K | SEC |
| Nov 17, 2025 | Gregoire Sylvie | Director | Buy | 1,693 | $7.55 | $13K | SEC |
| Nov 17, 2025 | Gregoire Sylvie | Director | Buy | 1,707 | $7.57 | $13K | SEC |
| Nov 17, 2025 | ALAM JOHN J | CEO | Buy | 1,707 | $7.57 | $13K | SEC |
| Nov 17, 2025 | ALAM JOHN J | CEO | Buy | 1,693 | $7.55 | $13K | SEC |
| Nov 17, 2025 | ALAM JOHN J | CEO | Buy | 4,447 | $7.51 | $33K | SEC |
| Nov 17, 2025 | Winton Matthew | Executive Officer | Buy | 10,000 | $7.57 | $76K | SEC |
In the last 12 months CervoMed Inc. insiders made open-market purchases worth about $3.7 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in CRVO was filed on 2026-06-15.
37 investment managers reported holding CRVO in SEC Form 13F filings for Q2 2026.
No congressional trades in CRVO were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).